Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...
Bernstein analyst William Pickering maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price ...
Shares of Vertex Pharmaceuticals Inc. VRTX advanced 1.11% to $491.64 Wednesday, on what proved to be an all-around favorable ...
TD Cowen analyst Phil Nadeau maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of ...
With a market cap of $124.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology company. The Boston ...
The stock's rise snapped a four-day losing streak.
2d
Vertex Pharmaceuticals Incorporated ( NASDAQ: VRTX) TD Cowen 45th Annual Health Care Conference Transcript March 3, 2025 3:10 PM ET David Altshuler - Executive Vice President, Global Research and CSO ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Vertex Pharmaceuticals has outperformed the broader healthcare sector over the past year. Despite a 6.3% drop from its ...
Vertex Pharmaceuticals secured a Buy rating from Leerink Partners analyst David Risinger. The firm’s newly approved pain ...
In this article, we are going to take a look at where Vertex, Inc. (NASDAQ:VERX) stands against the other software stocks. Gartner projects that global software spending will rise by 14.2% in 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback